Maintenance therapy for AML after allogeneic HCT

Allogeneic hematopoietic cell transplant (allo-HCT) for eligible patients with acute myeloid leukemia (AML) in first complete remission is a central treatment paradigm to achieve durable remission. However, disease relapse after allo-HCT remains a significant concern and generally portends a poor pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nayak, Rahul K., Chen, Yi-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397403/
https://www.ncbi.nlm.nih.gov/pubmed/36016625
http://dx.doi.org/10.3389/fonc.2022.895771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397403/
https://www.ncbi.nlm.nih.gov/pubmed/36016625
http://dx.doi.org/10.3389/fonc.2022.895771

Ejemplares similares